Harbor Capital Advisors Inc. Boosts Stake in LivaNova PLC (NASDAQ:LIVN)

Harbor Capital Advisors Inc. grew its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 101.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 84,913 shares of the company's stock after acquiring an additional 42,728 shares during the period. Harbor Capital Advisors Inc. owned about 0.16% of LivaNova worth $3,335,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UMB Bank n.a. increased its stake in LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after acquiring an additional 647 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of LivaNova by 2,299.7% in the 1st quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock worth $344,000 after buying an additional 8,394 shares in the last quarter. Central Pacific Bank Trust Division raised its position in shares of LivaNova by 7.0% in the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock valued at $173,000 after buying an additional 290 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of LivaNova during the 4th quarter worth $8,897,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of LivaNova in the fourth quarter valued at about $4,812,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

LIVN stock traded down $0.21 during mid-day trading on Thursday, hitting $46.49. The company had a trading volume of 81,829 shares, compared to its average volume of 642,505. The company has a market capitalization of $2.53 billion, a price-to-earnings ratio of 110.69 and a beta of 0.90. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a 50-day moving average price of $40.12 and a 200 day moving average price of $43.99. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $57.35.

Wall Street Analyst Weigh In

LIVN has been the topic of several analyst reports. Barclays lowered their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Tuesday, May 13th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Stifel Nicolaus lowered their target price on LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Finally, Robert W. Baird raised their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, LivaNova presently has an average rating of "Buy" and a consensus target price of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.